Peptides and blood sugar: MK-677, IGF-1 and GLP-1 hypoglycaemia risks
Last updated: October 27, 2026 · 7 min read · By the Grey Peptides Editorial Board
- MK-677 and other growth hormone boosters tend to raise blood sugar and reduce insulin sensitivity; in a two-year trial in older adults, fasting glucose rose.
- IGF-1, the hormone growth hormone works through, does the opposite: the approved form can cause severe hypoglycaemia with seizures and must be taken with food.
- GLP-1 drugs lower blood sugar and can cause lows; their labels say the risk rises when they are combined with insulin or sulfonylureas.
- Stacks that combine these push glucose in opposite directions at different speeds, and we found no study of them together.
Why peptides move blood sugar at all
Peptides that act on the growth hormone and incretin systems do not all push blood sugar the same way. The label for somatropin (growth hormone) warns that impaired glucose tolerance and diabetes may be unmasked and advises monitoring glucose in all patients (drug label) 1. IGF-1, which growth hormone stimulates, has insulin-like effects and can drive glucose down 2. GLP-1 drugs increase insulin release when glucose is high 3.
The result is that two peptides taken together can have opposite effects on glucose. The table summarises the direction of each.
| Compound (example) | Usual effect on blood sugar | Main evidence |
|---|---|---|
| MK-677 (ibutamoren), a growth hormone secretagogue | Raises it; lowers insulin sensitivity | Randomised trials in older and obese adults |
| Growth hormone (somatropin) and tesamorelin | Can raise it; labels warn of glucose intolerance and diabetes | Drug labels; tesamorelin trials |
| IGF-1 (mecasermin) and IGF-1 LR3 | Lowers it; can cause severe hypoglycaemia | Mecasermin label and registry; animal studies of LR3 |
| GLP-1 drugs (semaglutide, tirzepatide) | Lowers it; risk of lows rises with insulin or sulfonylureas | Drug labels |
MK-677: the most studied glucose raiser
MK-677, or ibutamoren, is an oral ghrelin mimetic that raises growth hormone and IGF-1 4. In a randomised trial in 32 adults aged 64 to 81 given placebo or 2, 10 or 25 mg daily, MK-677 raised fasting glucose from 5.4 to 6.8 mmol/L at four weeks compared with baseline (randomised trial) 5. In 24 obese men, eight weeks of 25 mg did not change fasting glucose or insulin, but glucose tolerance tests showed impairment at two and eight weeks (randomised trial) 6.
The longest trial gave MK-677 or placebo to healthy older adults for two years. MK-677 raised growth hormone and IGF-1 to young-adult levels and increased fat-free mass, but body weight rose by 2.7 kg against 0.8 kg on placebo, fasting glucose rose by an average of 0.3 mmol/L (5 mg/dL), and insulin sensitivity fell (randomised trial in 65 adults aged 60 to 81) 4. In 18 children with growth hormone deficiency given it for seven or eight days, glucose and insulin did not change (randomised trial) 7.
MK-677 was never approved; its development as a drug was discontinued 8.
Growth hormone, tesamorelin and other secretagogues
The same direction applies, to varying degrees, to approved drugs that raise growth hormone. Besides somatropin's warning 1, the label for tesamorelin (EGRIFTA WR), a GHRH analogue, warns that glucose intolerance or diabetes may develop and advises evaluating glucose before and during therapy (drug label) 9. In trials, the effect was modest: in 50 people with HIV, fasting glucose rose by 7 mg/dL more than placebo at two weeks but fasting and two-hour glucose did not differ by six months (randomised trial) 10; over a year in 61 people with HIV and fatty liver, fasting glucose and HbA1c did not differ from placebo (randomised trial) 11; and in 53 people with type 2 diabetes, 12 weeks did not worsen diabetes control (randomised trial; one author from the maker, Theratechnologies) 12.
This page cites no glucose study for the research secretagogues ipamorelin, CJC-1295 or the GHRPs; whether and how much they raise glucose is not established here.
IGF-1: the opposite direction, and the most dangerous
IGF-1 lowers blood sugar directly. The approved form, mecasermin (INCRELEX), used for a rare childhood IGF-1 deficiency, carries a prominent warning: severe hypoglycaemia leading to seizures has been observed, so it must be given within 20 minutes of a meal or snack, glucose should be monitored while the dose is adjusted, and patients should avoid high-risk activities such as driving or exercise for two to three hours after a dose (drug label) 2. If lows occur despite adequate food, the label says the dose should be reduced 2. A European registry analysis of 306 treated children and adolescents found about 0.11 hypoglycaemia events per patient per year of treatment, and 0.01 serious events; three of its authors worked for Ipsen (registry study) 13.
For IGF-1 LR3, an analogue sold online as a research peptide, a PubMed search on October 27, 2026 found no study that gave it to people; injected under the skin of calves it lowered blood glucose and insulin (animal evidence) 14, and in fetal sheep an infusion acutely suppressed insulin (animal evidence) 15.
GLP-1 drugs: lows and the combinations that raise the risk
Semaglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, according to its label 3. Their labels frame the hypoglycaemia risk around combinations. The Wegovy label says it lowers blood glucose and can cause hypoglycaemia, that the risk increases with insulin or insulin secretagogues such as sulfonylureas, and that reducing the dose of those drugs should be considered when starting it; it asks prescribers to tell all patients about the signs of low blood sugar (drug label) 3. The Mounjaro label gives the same advice for tirzepatide, and notes more hypoglycaemia in children aged 10 and over than in adults (drug label) 16.
Our guide to compounded and research tirzepatide covers how those products differ from the approved pens.
Why stacks are unpredictable
A growth hormone secretagogue, IGF-1 and a GLP-1 drug push glucose in opposite directions: MK-677 reduced insulin sensitivity over months 4, mecasermin can cause severe lows around a dose 2, and GLP-1 drugs lower glucose in a glucose-dependent way 3. A PubMed search on October 27, 2026 found no study combining MK-677 with IGF-1 or a GLP-1 drug, so there is no evidence on the net effect. The mecasermin label specifically warns about skipped meals and exercise within 2 to 3 hours of a dose 2.
Our Stack Safety Analyzer flags blood-sugar effects for each compound in a combination, using the same sources as this article.
Signs to watch for
The Wegovy label lists signs of low blood sugar including dizziness, sweating, shakiness, blurred vision, slurred speech, weakness, anxiety, hunger, headache, irritability, confusion or drowsiness and a fast heartbeat 3; the mecasermin label warns that severe lows can cause seizures and tells patients to avoid driving or exercise for 2 to 3 hours after a dose 2. For raised glucose, the somatropin and tesamorelin labels advise checking glucose before and during treatment 1 9.
Who should be most careful
- People with diabetes or prediabetes, or a strong family history: secretagogues and growth hormone can worsen glucose control, and glucose-lowering drug doses may need changing 1 4.
- Anyone taking insulin or a sulfonylurea who adds a GLP-1 drug: the labels advise considering a lower dose of the other drug 3 16.
- Anyone using IGF-1, especially without food or before exercise 2.
- Older adults, in whom MK-677's glucose rise was documented 5 4.
Questions to ask before using these peptides
- What is my fasting glucose or HbA1c now, and how will I check it while using this?
- Does this product raise or lower blood sugar, and does anything else I take do the opposite?
- Am I on insulin or a sulfonylurea, and has my prescriber been told?
- Do I know the signs of a low?
The bottom line
Peptides do not have one effect on blood sugar. MK-677 raised it and reduced insulin sensitivity in a two-year trial. IGF-1 lowers it, sometimes dangerously, which is why its approved form is given with meals and monitoring. GLP-1 drugs lower it, with the main risk of lows coming from combination with insulin or sulfonylureas. We found no study of these combined, so the net effect of a stack is unknown.
Frequently asked questions
Does MK-677 raise blood sugar?
Yes. In a two-year trial in healthy older adults, fasting glucose rose by about 0.3 mmol/L and insulin sensitivity fell; in a shorter trial of 2 to 25 mg, fasting glucose rose from 5.4 to 6.8 mmol/L over four weeks.
Can IGF-1 cause low blood sugar?
Yes. The approved IGF-1 drug, mecasermin, can cause severe hypoglycaemia with seizures and must be given within 20 minutes of a meal or snack.
Do GLP-1 drugs cause hypoglycaemia?
They lower blood sugar, and their labels say the risk of hypoglycaemia increases when they are combined with insulin or sulfonylureas, whose doses may need reducing.
Is it safe to stack MK-677 with IGF-1 LR3?
A PubMed search on October 27, 2026 found no study of the combination. They push blood sugar in opposite directions, so the net effect is unknown.
Should I check my blood sugar on growth hormone peptides?
Labels for approved growth hormone and tesamorelin advise monitoring glucose before and during therapy.
Related on Grey Peptides
Sources
- Pfizer. GENOTROPIN (somatropin) US prescribing information, Warnings and Precautions 5.4 (impaired glucose tolerance and diabetes mellitus). DailyMed version 37, effective August 4, 2026; read October 1 and October 27, 2026. DailyMed
- Eton Pharmaceuticals. INCRELEX (mecasermin) US prescribing information, Dosage and Administration, Warnings and Precautions 5.1 (Hypoglycemia) and Patient Information. DailyMed version 5, effective May 18, 2026; read October 1 and October 27, 2026. DailyMed
- Novo Nordisk. WEGOVY (semaglutide) US prescribing information, Warnings and Precautions 5.4, Drug Interactions 7.1, Clinical Pharmacology 12.2 and Patient Information. DailyMed version 19, effective June 18, 2026; read October 1 and October 27, 2026. DailyMed
- Nass, R., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med, 149(9), 601-11. PMID: 18981485
- Chapman, I. M., et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab, 81(12), 4249-57. PMID: 8954023
- Svensson, J., et al. (1998). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab, 83(2), 362-9. PMID: 9467542
- Codner, E., et al. (2001). Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther, 70(1), 91-8. PMID: 11452249
- Grey Peptides encyclopedia entry for MK-677 (ibutamoren): development status (discontinued), WADA status (S2.2.4, named). Read October 3, 2026.
- Theratechnologies. EGRIFTA WR (tesamorelin) US prescribing information, Warnings and Precautions 5.4 (glucose intolerance or diabetes mellitus). DailyMed version 2, effective July 29, 2026; read October 1 and October 27, 2026. DailyMed
- Stanley, T. L., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 312(4), 380-9. PMID: 25038357
- Stanley, T. L., et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 6(12), e821-e830. PMID: 31611038
- Clemmons, D. R., et al. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One, 12(6), e0179538. PMID: 28617838
- Bang, P., et al. (2023). Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry. J Clin Endocrinol Metab, 109(1), 46-56. PMID: 37579214
- Hammon, H., et al. (1998). Endocrine and metabolic changes in neonatal calves in response to growth hormone and long-R3-insulin-like growth factor-I administration. Biol Neonate, 73(2), 121-8. PMID: 9483305
- White, A., et al. (2023). Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. J Dev Orig Health Dis, 14(3), 353-361. PMID: 37114757
- Eli Lilly. MOUNJARO (tirzepatide) US prescribing information, Warnings and Precautions 5.3, Drug Interactions 7.1 and Pediatric Use 8.4. DailyMed version 40, effective August 27, 2026; read October 1 and October 27, 2026. DailyMed
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead